CLDN6 and neoplasm: Autologous CLDN6-CAR-NK cells were engineered to express CCL19/IL7 and scFv targeting PD-1/CTLA-4/Lag-3 to increase the anti-tumor efficacy against CLDN6-positive solid tumors [40].